Şadiye ALTUNTUZCU, Bekir TAŞDEMİR, İhsan KAPLAN, Ali UYAR, Fatih GÜZEL, Yunus GÜZEL, Mansur DAĞGÜLLİ

The relationship between 68Ga-PSMA uptake and Gleason Score and PSA levels in patients with prostate cancer

Aim: PSMA expression has been observed in increased levels in patients with high Gleason scores. Current information on Ga-68 PSMA PET/CT shows that primary staging with PET/CT is important in patients with high-risk PC. Ga-68 PSMA PET/CT may also have a place in patients with intermediate risk PC, but only a few data are available at present. In this study, we aimed to elucidate the relationship between PSMA expression value in the prostate gland, total PSA levels and GS in patients diagnosed with prostate cancer. Material and Method: A total of 98 patients who were pathologically diagnosed with prostate cancer that did not receive any treatment and underwent Ga‐68 PSMA PET/CT imaging for staging were included in the study. Findings detected in Ga‐68 PSMA PET/CT imaging were categorized as prostate, lymph node, bone, and visceral organ. The focal increased PSMA expression values observed in the prostate gland were recorded as SUVmax. The patients were divided into two separate groups according to their GS score (GS>7 and GS≤7). Correlations between prostate PSMA SUVmax, GS score and total PSA scores were investigated. Results: PSMA SUVmax levels of the group with a Gleason score of >7 were found to be significantly higher than the group with a Gleason score of ≤7 (p=0.03). The rates of lymph node metastasis, bone metastasis and visceral organ metastases were found to be significantly higher in the group with a Gleason score >7 compared to the group with a Gleason score ≤7. A positive correlation was observed between PSMA SUVmax and Total PSA (r=0.260, p=0.01). A positive correlation was observed between PSMA SUVmax and Gleason score (r=0.260, p=0.01). A positive correlation was observed between total PSA and Gleason score (r=0.320, p=0.001). Conclusion: In conclusion, PSMA SUVmax and Total PSA levels were higher in the group with high Gleason score. There is a positive correlation between PSMA SUVmax and total PSA. Clinicians should be careful in this regard, as the possibility of metastasis will be high in groups with high Gleason scores.

Keywords:

Prostate specific membrane antigen, prostate cancer, Ga‐68 PSMA PET/CT, Prostate specific membrane antigen, prostate cancer, Ga‐68 PSMA PET/CT,

PDF

___

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: 359-86.
2.Siegel RL, Sahar L, Portier KM, et al. Cancer death rates in US congressional districts. CA Cancer J Clin 2015; 65: 339-44.
Thomas L, Balmus C, Ahmadzadehfar H, Essler M, Strunk H, Bundschuh RA. Assessment of bone metastases in patients with prostate cancer-a comparison between (99m)Tc-bone-scintigraphy and [(68)Ga]Ga-PSMA PET/CT. Pharmaceuticals (Basel) 2017; 31: 10.
Lengana T, Lawal IO, Boshomane TG, et al. (68)Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer 2018; 16: 392-401.
Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relationto PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016; 43: 397- 403.
National Comprehensive Cancer Network. NCCN Clinical Guidelines in Oncology. Prostate Cancer. Version 2.2020. 2020; https://www.nccn.org/professionals/physician_gls/pdf/prostate. pdf
Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017; 44: 1014-24.
Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011; 65: 1180-92.
Siegel RL, Sahar L, Portier KM, et al. Cancer death rates in US congressional districts. CA Cancer J Clin 2015; 65: 339-44.
Topuz ÖV, Aksu A, Erinç SR, Tamam MÖ.Correlations of 68 Ga-PSMA PET/CT in the initial staging of prostate cancer patients. Hell J Nucl Med 2021; 24: 60-65.
Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114-21.
Sridhar SS, Freedland SJ, Gleave ME, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol 2014; 65: 289-99.
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017; 10
Bailey J, Piert M. Performance of 68Ga‐PSMA PET/CT for prostate cancer management at initial staging and time of biochemical recurrence. Curr Urol Rep 2017; 18: 84.
Lenzo NP, Meyrick D, Turner JH. Review of Gallium‐68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics (Basel, Switzerland) 2018; 8: 16.
Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga‐PSMA‐11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44: 941–9.
Klingenberg S, Jochumsen MR, Ulhøi BP, et al. (68)Ga-PSMA PET/CT for primary lymph node and distant metastasis NM staging of high-risk prostate cancer. J Nucl Med 2021; 62: 214-20.
Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga‐PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015; 56: 668–74.
Chun FK‐H, Steuber T, Erbersdobler A, et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol. 2006; 49: 820–6.
Ceci F, Uprimny C, Nilica B, et al. (68)Ga‐PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imag 2015; 42: 1284–94.
Öbek C, Doğanca T, Demirci E, et al. Members of Urooncology Association, Turkey. the accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2017; 44: 1806-12.
Mottet N, Bellmunt J, Briers E. et al. Members of the EAU-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Amsterdam 2020. 978-94-92671-07-3. Arnhem: EAU Guidelines Office; 2020.
Calais J, Fendler WP, Eiber M, et al. Impact of 68Ga-PSMA-11PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 2018; 59: 434-41.
Sonni I, Eiber M, Fendler WP, et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single center study. J Nucl Med 2020; 61: 1153-60.
Uprimny C, Kroiss AS, Decristoforol C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour, Eur J Nucl Med Mol Imaging 2017; 44: 941–9.